UBS Group
PYXS icon

UBS Group’s Pyxis Oncology PYXS Stock Holding History

UBS Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$467K Sell
155,217
-98,907
-39% -$189K ﹤0.01% 6277
2026
Q1 		$371K Sell
254,124
-138,642
-35% -$209K ﹤0.01% 6282
2025
Q4 		$452K Buy
392,766
+19,039
+5% +$67.2K ﹤0.01% 6156
2025
Q3 		$830K Sell
373,727
-22,369
-6% -$32.2K ﹤0.01% 5718
2025
Q2 		$436K Sell
396,096
-748
-0.2% -$843 ﹤0.01% 6123
2025
Q1 		$389K Sell
396,844
-49,855
-11% -$66.5K ﹤0.01% 6051
2024
Q4 		$697K Buy
446,699
+418,597
+1,490% +$1.21M ﹤0.01% 5613
2024
Q3 		$103K Buy
28,102
+10,424
+59% +$36.5K ﹤0.01% 6334
2024
Q2 		$58.5K Sell
17,678
-10,572
-37% -$44.4K ﹤0.01% 6570
2024
Q1 		$120K Buy
28,250
+25,295
+856% +$106K ﹤0.01% 6135
2023
Q4 		$5.32K Hold
2,955
– – ﹤0.01% 7795
2023
Q3 		$5.88K Sell
2,955
-4,695
-61% -$10.9K ﹤0.01% 7335
2023
Q2 		$19.6K Buy
7,650
+4,695
+159% +$14.9K ﹤0.01% 6879
2023
Q1 		$11.8K Buy
+2,955
New +$5.9K ﹤0.01% 7472
2022
Q4 		– Sell
-155
Closed – – 11054
2022
Q3 		$0 Sell
155
-212
-58% -$554 ﹤0.01% 10806
2022
Q2 		$1K Sell
367
-1,065
-74% -$2.83K ﹤0.01% 9939
2022
Q1 		$6K Sell
1,432
-3,386
-70% -$24.8K ﹤0.01% 8984
2021
Q4 		$53K Buy
+4,818
New +$55.2K ﹤0.01% 6843

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's PYXS Position: Q2 2026 in Review

UBS Group reduced its Pyxis Oncology (PYXS) stake by 39% in Q2 2026, selling an estimated $189K and leaving 155,217 shares worth $467K. The position accounts for ﹤0.01% of the portfolio, ranked #6277.

UBS Group first reported a position in PYXS in Q4 2021 and has held it in 18 quarters since. The position peaked at $830K in Q3 2025. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • UBS Group held 155,217 shares of Pyxis Oncology worth $467K as of Q2 2026.
  • UBS Group sold 98,907 Pyxis Oncology shares in Q2 2026, an estimated $189K.
  • Pyxis Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6277 holding.
  • UBS Group first reported a position in Pyxis Oncology in Q4 2021 and has held it in 18 quarters since.
  • UBS Group's Pyxis Oncology position peaked at $830K in Q3 2025.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.